|

Lymphodepleting chemotherapy Clinical Trials

7 actively recruiting trials across 2 locations

No change since May 2026

Also known as: Fludarabine (Fludara®)

Pipeline

Phase 1: 2Phase 1/2: 5

Top Sponsors

  • Beijing Biotech5
  • Washington University School of Medicine1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer7
  • Lung Cancer2
  • Relapsed/Refractory SCLC1
  • Recurrent or Refractory Disease After Standard Therapies1
  • Growth Factor1

Other5 trials

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Phase 1/2
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/2
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
Phase 1/2

St Louis, Missouri1 trial

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Washington University School of Medicine

Phase 1

Houston, Texas1 trial

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

MD Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.